Retatrutide 30mg

Retatrutide 30mg – GLP-1/GIP/Glucagon Triple Agonist

Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly that simultaneously acts on GLP-1, GIP, and glucagon receptors. In the Phase 3 TRIUMPH-1 clinical trial (May 2026), Retatrutide delivered the strongest published weight-reduction data for any medication to date.

This 30mg vial covers extensive research series and long-term animal-based studies.

Mechanism of action

By simultaneously activating three metabolic pathways, Retatrutide exerts a synergistic effect on energy balance, insulin sensitivity, and fat breakdown. In TRIUMPH-1, participants on the 12 mg dose lost on average 28.3 % of their body weight after 80 weeks — in participants with a BMI ≥35 even up to 30.3 % after 104 weeks. Even lower doses showed strong effects: 9 mg → 25.9 %, 4 mg → 19.0 %.

Technical specifications

Storage: Store at −20 °C (long-term); after reconstitution at 4 °C, use within 2–4 weeks. Protect from light and moisture.

Source: Eli Lilly TRIUMPH-1 Phase 3 study, May 2026

Disclaimer: Not intended for human or veterinary use. For laboratory research purposes only. Not for diagnostic or therapeutic purposes.

Reconstitution note 30 mg: This vial size reduces the number of reconstitutions required in larger study series and is suitable for protocols with longer observation periods.

Reconstitution: Example calculation

To achieve a working concentration of 10 mg/ml, reconstitute the 30 mg vial with 3 ml of sterile bacteriostatic water (BAC water). Slowly inject the water along the inside of the vial and gently swirl it instead of shaking it to avoid damaging the peptide structure. Detailed step-by-step instructions can be found in our user manual.

Frequently Asked Questions

For what study length is the 30 mg dose suitable?
The 30 mg vial size is suitable for more extensive test series with multiple measurement points over a longer observation period without having to restart the test in between.

Is the purity identical in larger vials?
Yes — each batch is tested for the same ≥98.9 %-HPLC purity, regardless of vial size, and is delivered with its own certificate of analysis.

Quality assurance

Each production batch undergoes independent dual testing: HPLC analysis (High Performance Liquid Chromatography) to determine purity and LC-MS analysis (Liquid Chromatography Mass Spectrometry) to definitively verify molecular mass and correct peptide sequence. Only after passing these tests is a batch released.